NL-OMON50106撤回2 期
Pan Tumor Study for Long Term Follow-up of Cancer Survivors Who Have Participated in Trials Investigating Nivolumab - BMS CA209-8TT: Pan tumor Nivolumab Rollover Study
Bristol-Myers Squibb0 个研究点目标入组 10 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 撤回
- 发起方
- 入组人数
- 10
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •* Signed Written Informed Consent
- •* Participants who have completed treatment with nivolumab, progressed on prior
- •nivolumab treatment or discontinued nivolumab due to toxicity, in the Parent
- •Study are not eligible to receive nivolumab in this study. These participants
- •may be enrolled for safety and survival follow-up only.
- •* Participant is eligible for nivolumab treatment as per the Parent Study
- •and/or Investigator assessed clinical benefit
排除标准
- •For Participants planning to enter the study on nivolumab treatment:
- •* Participant is not eligible for nivolumab treatment as per the Parent Study
- •* Participants not receiving clinical benefit as assessed by the Investigator
- •(participant is still eligible for study if entering survival follow-up only)
- •* Any clinical adverse event (AE), laboratory abnormality, or intercurrent
- •illness which, in the opinion of the Investigator, indicates that participation
- •in the study is not in the best interest of the participant
- •* History of allergy or hypersensitivity to study drug components
- •* Prisoners or participants who are involuntarily incarcerated (Note: Under
- •certain specific circumstances and only in countries where local regulations
- •permit, a person who has been imprisoned may be included or permitted to
- •continue as a participant. Strict conditions apply and Bristol-Myers Squibb
- •approval is required.)
- •* Participants who are compulsorily detained for treatment of either a
- •psychiatric or physical (eg, infectious disease) illness
- •* Dementia or serious psychiatric condition that may compromise the informed
- •consent process and increase the risks associated with study participation
- •* Participants with any condition which, in the judgment of the Investigator,
- •may pose a significant risk to the subject
- •* Participants in survival follow-up have no exclusion criteria.
研究者
相似试验
进行中（未招募）
1 期
Study to evaluate long-term safety of nivolumab for subjects with cancer who will be provided nivolumab or have finished treatment and are now in or have completed follow up on another study of nivolumab or nivolumab combinatiopan tumorMedDRA version: 20.0Level: LLTClassification code 10007050Term: CancerSystem Organ Class: 100000004864EUCTR2018-004362-34-PTBristol-Myers Squibb International Corporation1,231
进行中（未招募）
1 期
Study to evaluate long-term safety of nivolumab for subjects with cancer who will be provided nivolumab or have finished treatment and are now in or have completed follow up on another study of nivolumab or nivolumab combinatiopan tumorMedDRA version: 20.0Level: LLTClassification code 10007050Term: CancerSystem Organ Class: 100000004864EUCTR2018-004362-34-ESBristol-Myers Squibb International Corporation1,231
进行中（未招募）
1 期
Study to evaluate long-term safety of nivolumab for subjects with cancer who will be provided nivolumab or have finished treatment and are now in or have completed follow up on another study of nivolumab or nivolumab combinatiopan tumorMedDRA version: 20.0Level: LLTClassification code 10007050Term: CancerSystem Organ Class: 100000004864EUCTR2018-004362-34-NLBristol-Myers Squibb International Corporation1,231
进行中（未招募）
1 期
Study to evaluate long-term safety of nivolumab for subjects with cancer who will be provided nivolumab or have finished treatment and are now in or have completed follow up on another study of nivolumab or nivolumab combinatioEUCTR2018-004362-34-NOBristol-Myers Squibb International Corporation1,231
进行中（未招募）
1 期
Study to evaluate long-term safety of nivolumab for subjects with cancer who will be provided nivolumab or have finished treatment and are now in or have completed follow up on another study of nivolumab or nivolumab combinatiopan tumorMedDRA version: 20.0Level: LLTClassification code 10007050Term: CancerSystem Organ Class: 100000004864EUCTR2018-004362-34-GBBristol-Myers Squibb International Corporation1,231